Brief: Cartesian Therapeutics Announces First Patient Dosed In Phase 2 Trial Of Descartes-08 In Systematic Lupus Erythematosus
02/07/2024 11:51
July 2 (Reuters) - Cartesian Therapeutics Inc RNAC.O :
* CARTESIAN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 2
TRIAL OF DESCARTES-08 IN SYSTEMATIC LUPUS ERYTHEMATOSUS
Source text for Eikon: ID:nGNX41Q82j
Further company coverage: RNAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview